louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00172887: Needs Assessment of Long-Term Care for Psychiatric Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mental Disorders
Keywords: Psychiatrists
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Department of Health, Executive Yuan, R.O.C. (Taiwan)
First posted: 2005-09-15
Enrollment: 1150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: The quantity and quality of inpatient services for persons with psychiatric illness have been enhanced in the last two decades. Following the enforcement of nationwide health insurance and the Physically and Mentally Disabled Citizens Protection Act, the financial pressure of medical care for psychiatric patients is relieved, and actions related to the protection of patients' human rights have been taken. Nonetheless, problems related to psychiatric illness are not limited to symptoms. Patients' daily functions are affected and it causes continuous pressure on the family. Currently, psychiatric care places more emphasis on inpatient services. Once the patient is discharged from the hospital, related psychiatric services are not widely available, which leads to symptom exacerbation, repeated hospital admissions, increased burden to the family, etc. A provision of continuous long-term care that meets the various needs of psychiatric patients is a critical issue in current psychiatric care.

Based on a three-phase needs assessment model, the purpose of the study is to evaluate the needs of long-term care for psychiatric patients. The first phase will identify the current status of needs from the perspectives of patients and the family, psychiatric professionals, and the system. The second phase will identify the goals of long-term care for psychiatric patients. The goals will be identified by a nominal group, composed of experts related to the field of psychiatric long-term care. The third phase will determine the objectives of long-term care services for psychiatric patients. That is to determine the proper contents of long-term care services for the patients based on the goals identified in the previous phase.

The three-phase needs assessment will be carried out in a two-year period. The results of the study will provide important information to the future planning of long-term care for psychiatric patients.

Detailed description: First, the participants were informed about how to fill in the self-report survey questionnaire. Then the participants began to complete the questionnaire. After finishing it, the participants gave the questionnaire back to the examiner.

Eligibility criteria: Inclusion Criteria:

* Psychiatric patient
* Must be able to read Chinese
* Caregivers of psychiatric patients

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Department of Occupational Therapy, National Taiwan University
name: Chinyu Wu, Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT04254887: Effect of EPBD in ERCP on the Prognosis of Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula
Official title: EPBD+Small EST VS. Large EST in Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periampullary Diverticula
Keywords: EPBD
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 128
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesized that nipple balloon dilatation could make ERCP more successful and reduce postoperative complications and mortality. So the investigators design this experiment on this assumption.

Detailed description: The incidence of periampullary diverticula in patients with choledocholithiasis is very high at 47.1%. A large number of literatures refered that duodenal papillary diverticulum is a high risk factor for postoperative complications and recurrence of choledocholithiasis . Till now, there have been no randomized controlled trials to explore the effect of nipple balloon dilatation (EPLBD) on the treatment and prognosis of patients with choledocholithiasis complicated with periampullary diverticula (found during ERCP).

Eligibility criteria: Inclusion Criteria:

1. Patients with choledocholithiasis. 2. During ERCP, the patient was diagnosed as choledocholithiasis combined with duodenal papillary diverticulum. 3. Ages 16 to 75. 4. choledocholithiasis no larger than 1.5 cm

Exclusion Criteria:

1. Patients with duodenal papillary tumor. 2. Pregnant. 3. Patients with gastrointestinal duct obstruction endoscopy who cannot be operated and who have endoscopic contraindications. 4. Patients with duodenoscopy contraindications. 5. Patients with severe pancreatitis and other serious diseases.

Primary outcomes:
measure: Incidence of complications
timeFrame: 1 month
measure: time of operation
timeFrame: 1-4 hours
measure: postoperative recurrent rate
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT00508287: Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
Official title: Randomized, Placebo-Controlled, Single-Dose, Crossover Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2007-07-27
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Type 2 diabetes for ≥ 3 months treated with metformin, thiazolidinedione, or sulfonylurea (either monotherapy or combination) or diet alone (drug naïve)
* Fasting plasma glucose: 126 - 240 mg/dL
* Hemoglobin A1c: 6 - 10%
* Estimated CrCl ≥ 60 mL/min
* ALT ≤ 1.5 x ULN and total bilirubin ≤ 2 x ULN
* Stable and well controlled hypertension and/or dyslipidemia
* Concomitant medications used for hypertension and/or dyslipidemia, thyroid hormone replacement therapy and low dose aspirin will be allowed if stable for at least 6 weeks

Exclusion Criteria:

* Women of childbearing potential
* Symptomatic diabetes with polyuria and/or polydipsia
* History of diabetic ketoacidosis or hyperosmolar nonketotic syndrome
* History of renal disease including diabetic nephropathy

Primary outcomes:
measure: Safety: incidence of adverse events
timeFrame: from subject enrollment to study discharge
Secondary outcomes:
measure: PK parameters: Cmax, Tmax, AUC(0-24h), AUC(INF) and T-HALF
timeFrame: from pre-dose to 24 hrs post-dose
measure: PD Measures: Fasting and postprandial serum glucose (AUC), serum insulin, and plasma glucagon concentrations. Acetaminophen plasma concentrations will be measured after a single dose of acetaminophen
timeFrame: from pre-dose to 9 hrs post-dose
Other outcomes:
Locations:
city: Miami
country: United States
facility: Elite Research Institute
state: Florida
city: Orlando
country: United States
facility: Orlando Clinical Research Center
state: Florida
city: Knoxville
country: United States
facility: New Orleans Center For Clinical Research
state: Tennessee
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT04382287: Comparison of Remineralisation Efficacy of MI PASTE Plus® and REMIN PRO® for White Spot Lesions in Primary Teeth
Official title: Comparison of Clinical Efficacy of MI PASTE Plus® and REMIN PRO® for the Remineralisation of Enamel White Spot Lesions in Primary Teeth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: White Spot Lesion
Keywords: Primary teeth
Enamel
Remineralisation
Lead sponsor: Universidad Autonoma de San Luis Potosí
Sponsor class: OTHER
First posted: 2020-05-11
Enrollment: 123
Sex: ALL
Minimum age (years): 2
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A randomised double-blind clinical trial, with three parallel study groups (two experimental and one control), whose participants were randomly assigned to one of te three groups.
Primary purpose: TREATMENT

Brief summary: The present study aimed to compare the remineralisation capacity of white spot enamel lesions between two commercially available tooth pastes (Remin Pro and MI PASTE PLUS), applied at home twice a day on the anterior upper primary teeth by the patient and parents.

Detailed description: Objective: To evaluate and compare the clinical efficacy of Remin Pro® and MI Paste Plus® for the remineralisation of white spot lesions (WSL) on the enamel of primary teeth.

Methods: The selected design for this study was a randomised double-blind clinical trial based on CONSORT guidelines. Patients with at least one upper anterior primary tooth with a WSL on the enamel surface, with units of fluorescence (UF) ranged from 11-20 (evaluated with DIAGNOdent) were included in the study. Patients were randomly assigned to receive either the twice-daily at-home topical application of Remin Pro® or MI Paste Plus® (both as experimental pastes) or Colgate Total® (as control paste). The degree of remineralisation was quantified by the change in the number of UF from the baseline evaluation and at days 10 and 21. The difference between groups was statistically evaluated using ANCOVA and ANOVA techniques.

Eligibility criteria: Inclusion Criteria:

* Young paediatric patients with at least one upper anterior primary tooth exhibiting one or several WSL on the smooth enamel surface.
* Attending the Paediatric Dentistry Postgraduate Program's Clinic
* Enamel lesions with units of fluorescence (UF) ranging from 11-20 as determined by DIAGNOdent
* Signed Informed Consent

Exclusion Criteria:

* History of hypersensitivity to any of the compounds of the pastes
* Enamel hypoplasia
* Compromising systemic diseases

Primary outcomes:
measure: Enamel remineralisation degree
timeFrame: 10 days
measure: Enamel remineralisation degree
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
city: San Luis Potosi
country: Mexico
facility: Faculty of Dentistry, Universidad Autónoma de san Luis Potosi
Study officials:
affiliation: San Luis Potosi University
name: Amaury Pozos-Guillén, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04200287: Study to Improve Survivorship Care Related to Fertility and Family-building After Cancer
Official title: Pilot Study to Improve Survivorship Care Related to Fertility and Family-building After Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2019-12-16
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this research is to explore how a patient decision aid tool (website) given to patients prior to their survivorship care visits, may impact patient-provider communication about fertility and family-building after cancer; and assess the impact of using the tool on patient reported outcomes. The overall purpose of this research is to improve survivorship care by establishing a multi-disciplinary approach to managing cancer and fertility issues and prompt early referral to supportive and medical care resources.

Detailed description: Objective 1: Establish feasibility and acceptability of conducting research with YA-F cancer survivors at the Stanford Cancer Institute (SCI) and Lucile Packard Children's Hospital (LPCH).

Hypothesis 1: Study procedures will be feasible in the given timeframe and acceptable to patients, as evidence by recruitment, enrollment, and completion rates and participant feedback.

Objective 2: Evaluate the impact of using the tool as a part of survivorship care on patient reported outcomes (PROs; i.e., information needs, fertility distress, decision-making uncertainty, and satisfaction with care).

Hypothesis 2: In a single-arm pilot study (N=20), use of the decision aid tool will lead to improvements in fertility distress, decision-making uncertainty, and satisfaction with care.

Eligibility criteria: Inclusion Criteria:

* completed cancer treatment at least 6-months prior, excluding long-term adjuvant or maintenance therapies
* report an interest in discussing fertility/family-building with a provider
* understands verbal and written English
* access to the Internet and use of a computer, tablet, or smartphone
* has a scheduled cancer survivorship visit within the study time frame

Exclusion Criteria:

* Prior hospitalization for a mental disorder or history of psychosis

Note: Survivors on adjuvant maintenance or endocrine treatment, such as tamoxifen, will not be excluded because clinical guidelines allow treatment delay or hiatus to accommodate fertility

Primary outcomes:
measure: Decisional Conflict Scale (DCS)
timeFrame: 6 weeks
Secondary outcomes:
measure: Unmet Fertility Information
timeFrame: 6 weeks
measure: Reproductive Concerns After Cancer (RCAC) Scale
timeFrame: 6 weeks
measure: COMRADE
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Medical Center
state: California
Study officials:
affiliation: Stanford University
name: Catherine Benedict
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04235387: Haemodynamic Changes During Robotic Prostatectomy
Official title: Analysis of Haemodynamic Parameters of Patients Undergoing Robotic Prostatectomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Robotic Surgical Procedures
Keywords: robotic surgical procedures
laparoscopic surgical procedures
prostatectomy
haemodynamic changes
ventilatory changes
Lead sponsor: Czech Technical University in Prague
Sponsor class: OTHER
Collaborators: name: University Hospital, Motol
First posted: 2020-01-21
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing prostatectomy in University Hospital in Motol between 1st December 2019 and 30th April 2020.

Brief summary: The aim of the study is to analyse the haemodynamic and ventilatory changes in patients undergoing robotic prostatectomy, compared to standard laparoscopic prostatectomy.

Detailed description: Prostatectomy is a standard operation, increasingly performed using robotic assistance. During robotic assisted procedures, the intraabdominal pressures are usually higher than in standard laparoscopic operations which can pose a risk of cardiovascular and respiratory adverse effects. The aim of this study is to investigate the haemodynamic and ventilatory effects of robotic assisted prostatectomy, compared to standard laparoscopic prostatectomy.

Eligibility criteria: Inclusion Criteria:

* patients undergoing prostatectomy in University Hospital in Motol between 1st December 2019 and 30th April 2020

Exclusion Criteria:

* body mass index over 35
* regular use of beta-blocking drugs

Primary outcomes:
measure: Haemodynamic changes
timeFrame: Through study completion, an average of 1 year
measure: Ventilatory changes
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Praha
country: Czechia
facility: Motol University Hospital
city: Praha
country: Czechia
facility: Czech Technical University
Study officials:
affiliation: University Hospital in Motol
name: Tomas Vymazal, Ass.prof.
role: STUDY_CHAIR
References:
Clinical trial NCT01247987: Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes
Official title: Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: IVF, assisted reproduction, embryo transfer
Lead sponsor: Fertility Center of Las Vegas
Sponsor class: INDUSTRY
First posted: 2010-11-25
Enrollment: 140
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if cryopreservation at the blastocyst stage followed by embryo thaw and transfer is as effective as cryopreservation of bipronuclear oocytes followed by post-thaw extended culture (PTEC), and blastocyst transfer. Effectiveness will be measured by the rate of ongoing pregnancy at 10 weeks gestation.

Detailed description: Subjects will be randomized to one of two study groups during their cycles of in vitro fertilization (IVF). In one group, the subjects will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent cycle. In the other group, subjects will have all of their embryos cryopreserved at the bipronuclear oocyte stage, followed by thaw, extended culture, and transfer in a subsequent cycle.

Eligibility criteria: Inclusion Criteria:

1. Female patient seeking autologous in vitro fertilization (IVF) treatment.
2. Cycle day 3 serum concentration of follicle stimulating hormone (FSH) less than 10.0 IU/l.
3. Baseline total antral follicle count observed on ultrasound with at least eight antral follicles.
4. 18 to 40 years of age.
5. Ability to read and understand English.

Exclusion Criteria:

1. Embryo biopsy (a.k.a. pre-implantation genetic diagnosis (PGD)).
2. Any condition that, in the opinion of the physician or principal investigator, would place the patient at undue risk under this protocol or would otherwise make the protocol inappropriate for that subject.
3. No minors will be enrolled in this study.

Primary outcomes:
measure: Ongoing pregnancy rate
timeFrame: 10 weeks gestation
Secondary outcomes:
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: Fertility Center of Las Vegas
state: Nevada
Study officials:
References:
citation: Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Freeze-all at the blastocyst or bipronuclear stage: a randomized clinical trial. Fertil Steril. 2015 Nov;104(5):1138-44. doi: 10.1016/j.fertnstert.2015.07.1141. Epub 2015 Aug 5.
Clinical trial NCT06537687: Relational Agents in Cervical Cancer Education (RACE)
Official title: Relational Agents in Cervical Cancer Education (RACE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervix Cancer
Human Papilloma Virus
Vaginal Cancer
Vulvar Cancer
Lead sponsor: Barbara Ann Karmanos Cancer Institute
Sponsor class: OTHER
Collaborators: name: University of Oklahoma
First posted: 2024-08-05
Enrollment: 91
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this clinical trial is to assess the feasibility of using interactive teaching to educate cervical cancer patients about Human papillomavirus (HPV) and HPV vaccinations.


Eligibility criteria: Inclusion Criteria:

* Adults aged 18 and older
* Patients with an ICD9 diagnosis of cervical/vaginal/vulvar cancer or dysplasia receiving care at Karmanos Cancer Institute or OU Health Stephenson Cancer Center

Exclusion Criteria:

* Patients who are recorded in the EHR as requesting to be removed from research
* Non-English speakers
* Any cognitive disability that prevents informed consent
* Any individual recruited in previous phases of the Study will be excluded.

Primary outcomes:
measure: Participation Rate
timeFrame: Up to 6 weeks
measure: Survey Completion Rate
timeFrame: Up to 6 Weeks
Secondary outcomes:
measure: Change in intention to discuss HPV vaccination
timeFrame: Up to 6 weeks
measure: Change in Health Literacy
timeFrame: Up to 6 weeks
measure: Change in social norms and behaviors
timeFrame: Up to 6 weeks
measure: Change in Stigma
timeFrame: Up to 6 weeks
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Sciences Center
state: Oklahoma
Study officials:
affiliation: Karmanos Cancer Center
name: Radhika Gogoi, M.D. PhD
role: PRINCIPAL_INVESTIGATOR
References: